Moderna, Inc. Common Stock

Moderna's 18.33% short float is remarkably elevated, suggesting significant bearish positioning despite the stock trading 34% below its 52-week high. The RSI of 34.7 indicates oversold conditions, yet the absence of a P/E ratio signals the market questions profitability sustainability—a concerning signal for a $20.2B biotech company. This setup presents a classic compression dynamic: shorts may be vulnerable to a squeeze, but the lack of earnings power leaves the stock fundamentally vulnerable to further deterioration. The combination of elevated short interest and technical oversold readings creates asymmetric risk that leans toward caution despite oversold technicals.